Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Adam

Showing results (131-140 of 152) with videos related to

Pageof 16
Sort By:
Cancer Research|April 5, 2013
Cisplatin resistance associated with PARP hyperactivationJudith Michels, Ilio Vitale, Lorenzo Galluzzi, et al.
Archives of Pathology & Laboratory Medicine|July 8, 2017
Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology SocietyErik Thunnissen, Timothy Craig Allen, Julien Adam, et al.
JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
JCO Precision Oncology|September 14, 2020
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting <i>ALK</i> and <i>ROS1</i> Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung CancerLaura Mezquita, Aurélie Swalduz, Cécile Jovelet, et al.
The Journal of Clinical Investigation|February 16, 2018
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockadeMehdi Touat, Tony Sourisseau, Nicolas Dorvault, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2020
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni SyndromeLaura Mezquita, Maria Jové, Ernest Nadal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2022
Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell CarcinomaNadine Benhamouda, Ikuan Sam, Nicolas Epaillard, et al.
The New England Journal of Medicine|March 22, 2013
ERCC1 isoform expression and DNA repair in non-small-cell lung cancerLuc Friboulet, Ken André Olaussen, Jean-Pierre Pignon, et al.
JCO Precision Oncology|January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
The Journal of Clinical Investigation|May 3, 2022
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancerMathieu Rouanne, Julien Adam, Camélia Radulescu, et al.
Pageof 16

Showing results (131-140 of 152) with videos related to

Sort By:
Pageof 16
Cancer Research|April 5, 2013
Cisplatin resistance associated with PARP hyperactivationJudith Michels, Ilio Vitale, Lorenzo Galluzzi, et al.
Archives of Pathology & Laboratory Medicine|July 8, 2017
Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology SocietyErik Thunnissen, Timothy Craig Allen, Julien Adam, et al.
JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
JCO Precision Oncology|September 14, 2020
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting <i>ALK</i> and <i>ROS1</i> Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung CancerLaura Mezquita, Aurélie Swalduz, Cécile Jovelet, et al.
The Journal of Clinical Investigation|February 16, 2018
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockadeMehdi Touat, Tony Sourisseau, Nicolas Dorvault, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2020
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni SyndromeLaura Mezquita, Maria Jové, Ernest Nadal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2022
Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell CarcinomaNadine Benhamouda, Ikuan Sam, Nicolas Epaillard, et al.
The New England Journal of Medicine|March 22, 2013
ERCC1 isoform expression and DNA repair in non-small-cell lung cancerLuc Friboulet, Ken André Olaussen, Jean-Pierre Pignon, et al.
JCO Precision Oncology|January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
The Journal of Clinical Investigation|May 3, 2022
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancerMathieu Rouanne, Julien Adam, Camélia Radulescu, et al.
Pageof 16